University of Iowa Develops Gene Therapy to Prevent Craniosynostosis in Newborns
Key Insights
University of Iowa researchers successfully developed a gene therapy using miR-200a (search) delivered via 95-nanometer packets that prevented craniosynostosis (search) in all eight genetically programmed infant mice tested.
The treatment could replace invasive cranial vault remodeling surgery, which currently requires removing and reshaping skull bones and carries risks including blood transfusion needs, ICU stays, and rare fatalities.
The research team has applied to the FDA for human clinical trials and aims to begin testing in infants within one to two years, pending approval and additional safety studies.
University of Iowa researchers have achieved a significant breakthrough in treating craniosynostosis (search), developing the first gene therapy approach that could eliminate the need for invasive skull surgery in newborns. The team successfully prevented the condition in all eight genetically programmed infant mice using a single injection of nano-sized gene delivery packets.
Revolutionary Gene Therapy Approach
The research team identified miR-200a (search) as a key gene in preventing craniosynostosis (search) and created 95-nanometer delivery packets that migrate to skull joint regions when injected below the scalp. Brad Amendt, professor of anatomy and cell biology in the Carver College of Medicine and the study's corresponding author, explained the mechanism: "The cells have a process where they'll see this nanoparticle, take it up, and uncoat the particle, so that we can release the gene. Then a cell can express it."
Published in Science Advances on August 22, the study demonstrated that the gene therapy maintained open skull sutures for 17 days, allowing normal brain growth with no observed toxicity or adverse effects. "This is the first demonstration of a gene therapy approach for craniosynostosis (search) that we know of," Amendt said. "This will save a lot of trauma for children."
Addressing a Critical Medical Need
Craniosynostosis (search) affects approximately 1 out of every 2,000 to 2,200 babies when skull bones fuse prematurely, closing the sutural gaps that normally allow space for brain growth. If untreated, the condition can cause abnormal head shape and potentially impair brain development.
Current treatment involves cranial vault remodeling, a lengthy surgical procedure where surgeons use endoscopic tools to cut or reshape prematurely fused skull bones. Amy Galm, director of operations at CAPPSKids (search), a nonprofit supporting families with craniosynostosis (search), highlighted the surgery's risks: "Unfortunately, we've had a few children pass away during that surgery due to things like heart failure and bleeding. It's very horrible."
Some babies require blood transfusions or intensive care unit stays following the current surgical approach, making the potential for a simple injection-based treatment particularly significant.
Path to Clinical Translation
Amendt has applied to the FDA for approval to test the gene therapy on human infants, hoping to begin clinical trials within one to two years. The team faces several regulatory hurdles, including obtaining Good Manufacturing Practice (GMP) manufactured plasmid DNA and conducting additional safety studies.
The FDA typically prefers testing on larger animal models before human trials, presenting a unique challenge since craniosynostosis (search) rarely occurs in large animals. The research team plans to perform additional trials with different mouse models to demonstrate safety.
"This would be simple. It's cost effective. For the patients, it's noninvasive, which is the biggest thing," Amendt said. "It's pretty traumatic for a baby to undergo these types of surgeries where they have to have a piece of their skull removed, opened, and sutured up."
Clinical Impact and Future Implications
The gene therapy approach could transform treatment for families affected by craniosynostosis (search). Deborah Kacmarynski, associate professor in the UI Department of Otolaryngology and codirector of the Cleft and Craniofacial Team, noted the broader implications: "For those families who have other kiddos who've had [craniosynostosis] and are expecting a child, the idea that they could have kids who have much smaller surgical treatments available, or a single surgical treatment available, that's really meaningful for those people."
The research involved collaboration across multiple University of Iowa colleges, with Kevin Rice from the College of Pharmacy contributing to the nanoparticle formulation. The study was funded by the National Institutes of Health, the University of Iowa, and the Department of Orthodontics.
While early detection of craniosynostosis (search) before birth remains extremely limited, Kacmarynski believes advances in treatment options like gene therapy could motivate improvements in diagnostic capabilities, creating a positive cycle of medical advancement.